Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
SUBOXONE is a buprenorphine/naloxone combination film indicated for opioid use disorder maintenance treatment. Buprenorphine is a partial mu-opioid agonist that reduces cravings and withdrawal symptoms, while naloxone acts as an antagonist to deter misuse. The sublingual/buccal film formulation provides controlled delivery and improved patient convenience.
Product remains at peak lifecycle with strong market presence, but competitive pressure (8/10) signals sustained need for defensive marketing and field engagement teams.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population
Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
Transfer of Subjects From Subutex/Suboxone to RBP-6300
Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan
Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)
Worked on SUBOXONE at Indivior? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
Working on SUBOXONE offers exposure to a peak-stage product in a high-stakes therapeutic area with complex payer dynamics, regulatory oversight, and significant compliance requirements. However, the approaching 3.5-year LOE window means career trajectory is finite unless you transition to defense strategy, generics preparation, or related pipeline assets.